ADC Therapeutics SA Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ADC Therapeutics SA stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $118.00K, a 247.06% increase year-over-year.
- ADC Therapeutics SA stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $205.00K.
- ADC Therapeutics SA stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $219.00K, a 409.30% increase year-over-year.
- ADC Therapeutics SA stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $282.00K, a 154.05% increase year-over-year.
- ADC Therapeutics SA stock issued during period, value, stock options exercised for fiscal 2025 was $534.00K, a 134.21% increase from fiscal 2024.
- ADC Therapeutics SA stock issued during period, value, stock options exercised for fiscal 2024 was $228.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $118.00K 10-Q · filed 2026-08-13 | $824.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $205.00K 10-Q · filed 2026-05-04 | $740.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $534.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $282.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $34.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $228.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $111.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $41.00K 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $33.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |